Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Mutations in the leucine rich repeat kinase 2 gene (LRRK2) cause hereditary Parkinson’s disease. We have developed an easy and robust method for assessing LRRK2-controlled phosphorylation of Rab10 in human peripheral blood neutrophils. This may help identify individuals with increased LRRK2 kinase pathway activity.

Abstract

The leucine rich repeat kinase 2 (LRRK2) is the most frequently mutated gene in hereditary Parkinson’ disease (PD) and all pathogenic LRRK2 mutations result in hyperactivation of its kinase function. Here, we describe an easy and robust assay to quantify LRRK2 kinase pathway activity in human peripheral blood neutrophils by measuring LRRK2-controlled phosphorylation of one of its physiological substrates, Rab10 at threonine 73. The immunoblotting analysis described requires a fully selective and phosphospecific antibody that recognizes the Rab10 Thr73 epitope phosphorylated by LRRK2, such as the MJFF-pRab10 rabbit monoclonal antibody. It uses human peripheral blood neutrophils, because peripheral blood is easily accessible and neutrophils are an abundant and homogenous constituent. Importantly, neutrophils express relatively high levels of both LRRK2 and Rab10. A potential drawback of neutrophils is their high intrinsic serine protease activity, which necessitates the use of very potent protease inhibitors such as the organophosphorus neurotoxin diisopropylfluorophosphate (DIFP) as part of the lysis buffer. Nevertheless, neutrophils are a valuable resource for research into LRRK2 kinase pathway activity in vivo and should be considered for inclusion into PD biorepository collections.

Introduction

Attempts to slow or stop Parkinson’s disease (PD) have thus far failed. The discovery of hyperactivating mutations in the leucine rich repeat kinase 2 (LRRK2) that cause and/or increase the risk for PD has led to the development of LRRK2 kinase inhibitors1,2,3. These have now entered clinical trials4. The exact function of LRRK2 is unclear, but a major advancement has been the identification of a subset of Rab GTPase proteins, including Rab10, as the first bona fide physiological substrates of the LRRK2 kinase5,....

Protocol

According to local UK regulation all manipulations and pipetting of human blood are undertaken in a category 2 biological safety cabinet. All procedures were performed in compliance with local ethics review board and all participants have provided informed consent.

1. Preparation

  1. Prepare 0.1 mL of EDTA Stock Solution 1 containing 100 mM EDTA in phosphate-buffered saline (PBS).
  2. Prepare 60 mL of EDTA Stock Solution 2 containing 1 mM EDTA in PBS.
  3. Prepare lysis buff.......

Representative Results

Our assay allows interrogating the activation of the PD-associated LRRK2 kinase in human peripheral blood neutrophils with LRRK2-dependent Rab10 phosphorylation as a readout. Neutrophils are a homogenous and abundant peripheral white blood cell population that expresses high levels of both the LRRK2 and Rab10 proteins (Figure 1). The only other cell population among the remaining peripheral blood mononuclear cells (PBMCs) with high copy numbers of both proteins are monocytes, but these make .......

Discussion

Compelling clinical, genetic, and biochemical evidence points towards an important role for LRRK2 and in particular its kinase function in Parkinson’s disease7. LRRK2 kinase inhibitors have been developed and are entering clinical trials2,4,12. As such there is a need for exploiting LRRK2 as a biomarker for target engagement as well as patient stratification. Our protocol describes a robust and easy.......

Acknowledgements

We thank the healthy volunteers who kindly donated blood for the present study. We thank The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and the Fox BioNet study leadership (FBN) for their support and input towards the written protocol and the video. We thank Professor Alexander Zimprich from the University of Vienna in Austria for testing our protocol and collaboration. We value the contributions of Paul Davies to the project (general manager of the MRC PPU). We also recognize the excellent technical support of the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) namely Chemical Synthesis (Natalia Shpiro for synthesising MLi-2), MRC PPU R....

Materials

NameCompanyCatalog NumberComments
1 mL Pipette tipsSarstedt70.762or equivalent
1.5 mL Micro tubesSarstedt72.690.001or equivalent
10 mL Pipette tips Sarstedt86.1254.025 or equivalent
10 ÎĽL Pipette tipsSarstedt70.113or equivalent
15 mL falcon tube Cellstar188 271or equivalent
200 ÎĽL Pipette tipsSarstedt70.760.002or equivalent
25 mL Pipette tips Sarstedt86.1685.001or equivalent
50 mL falcon tube Cellstar227 261or equivalent
BD Vacutainer Hemogard Closure Plastic K2-EDTA TubeBD BD 367525or equivalent
Beckman Coulter Allegra X-15R centrifugeBeckmanor equivalent centrifuge with swimging bucket rotator for 15 mL and 50 mL falcon tubes at speed 1000-1200 x g
Category 2 biological safety cabinet.
cOmplete(EDTA-free) protease inhibitor cocktailRoche11836170001
DIFP (Diisopropylfluorophosphate) SigmaD0879Prepare 0.5M stock solution in isopropanol using special precautions 
Dimethyl sulfoxide Sigma6250
Dry ice or liquid nitrogene
Dulbecco's phosphate-buffered saline ThermoFisher14190094or equivalent
Easy 50 EasySep Magnet Stemcell18002for holding 1 x 50ml conical tube
EasySep Direct Human Neutrophil Isolation Kit Stemcell19666This contains Solutions called “Isolation Cocktail” and “RapidSpheres magnetic beads
EGTASigmaE3889
Eppendorf centrifuge 5417R centrifugeEppendorf
Ethanol, in spray bottle
Ethylenediaminetetraacetic acid SigmaE6758
Ice
Isopropanol (anhydrous grade) Sigma278475
Lysis buffer (50 mM Tris-HCl pH 7.5, 1%(v/v) Triton X-100, 1 mM EGTA, 1 mM Na3VO4, 50 mM NaF, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1% (v/v) β-mercaptoethanol, 1x cOmplete(EDTA-free) protease inhibitor cocktail (Roche), 1 μg/ml Microcystin-LR, 0.5 mM diisopropylfluorophosphate (DIFP). alternatively frozen lysis buffer in aliquots without Microcystin-LR, DIFP available from MRC-PPU Reagents (http://mrcppureagents.dundee.ac.uk/)
Merck LRRK2 inhibitor II (MLi-2)Merck438194-10MGor equivalent (potent and selective LRRK2 inhinitor)
Microcystin-LREnzo Life SciencesALX-350-012-M0011 mg/ml stock in DMSO and store at -80 oC. 
Na3VO4Aldrich450243
NaFSigmaS7920
Odyssey CLx scan Western Blot imaging systemOdyssey
Permanent marker pen
Personal protection equipment
RPMI 1640 Medium ThermoFisher21875034or equivalent
sodium pyrophosphateSigmaS22
sucroseSigmaS0389
β-glycerophosphateSigma50020
β-mercaptoethanolSigmaM3148
Suggested antibodies for Western blotting
Anti-RAB10 (phospho T73) antibody [MJF-R21]abcamab230261
Anti-α-tubulinCell Signaling Technologies5174used at 1:2000 dilution
Goat anti-mouse IRDye 680LTLI-COR926-68020used at 1:10,000 dilution
Goat anti-mouse IRDye 800CWLI-COR926-32210used at 1:10,000 dilution
Goat anti-rabbit IRDye 800CWLI-COR926-32211used at 1:10,000 dilution
MJFF-total Rab10 mouse antibodygenerated by nanoTools (nanotools.de)not applicable*used at 2 ÎĽg/ml final concentration; * The MJFF-total Rab10 antibody generated by nanoTools (www.nanotools.de) [11] will be commercialised by the Michael J Fox Foundation in 2018
Mouse anti-LRRK2 C-terminus antibodyAntibodies Incorporated 75-253used at 1 μg/ml final concentration
pS935-LRRK2MRC PPU Reagents and ServicesUDD2MJFF-total Rab10 mouse antibody

References

  1. Paisan-Ruiz, C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 44 (4), 595-600 (2004).
  2. Fell, M. J., et al.

Explore More Articles

Neutrophil IsolationLRRK2 KinaseRab10 PhosphorylationPeripheral BloodNegative SelectionEDTAMagnetic BeadsProtein Extraction

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved